NCT01772147已完成3 期
A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 608
- 试验地点
- 1
- 主要终点
- Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
研究概览
简要总结
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily with placebo when added to fluticasone propionate (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.
详细描述
This is a multicenter, randomized, double-blind, parallel-group study. Subjects who meet the eligibility criteria at screening and meet the randomization criteria at the end of a 4 week run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period after the treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type of subject: Outpatient.
- •Informed Consent: A signed and dated written informed consent prior to study participation.
- •Age: Subjects 40 years of age or older at Visit
- •Gender: Male or female subjects. A female is eligible to enter and participate if of non-child-bearing potential, or if of child bearing potential, has a megative serum pregnancy test at screening, and agrees to one of the acceptable contraceptive methods listed in the protocol, used consistently and correctly.
- •Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society.
- •Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit
- •Pipe and/or cigar use cannot be used to calculate pack year history.
- •Severity of Disease: A pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and a pre and post-albuterol/salbutamol FEV1 of ≤70% of predicted normal values at Visit 1 (Screening) calculated using Nutrition Health and Examination Survey (NHANES) III reference equations.
- •Dyspnea: A score of ≥2 on the mMRC Dyspnea Scale at Visit 1.
排除标准
- •-Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- •Asthma: A current diagnosis of asthma.
- •Other Respiratory Disorders: Known α-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to COPD should be excluded. Examples may include clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
- •Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for <5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that,in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
- •Contraindications: Any history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, corticosteroid (intranasal, inhaled or systemic) lactose/milk protein or magnesium stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholingeric.
- •Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit
- •Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit
- •12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit
- •Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix
- •The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix
- •Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
- •Medications Prior to Screening: use of certain medications for the protocol-specific times prior to Visit
- •Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤12 hours per day) is not exclusionary.
- •Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.
- •Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit
- •Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
- •Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit
- •Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, subinvestigator, study coordinator, or employee of the participating investigator.
- •Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a questionnaire.
研究组 & 干预措施
Fluticasone propionate/Salmeterol
Active Comparator
Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
干预措施: Fluticasone propionate 250mcg/Salmeterol 50mcg (Drug)
Umeclidinium bromide
Experimental
Long-acting muscarinic antagonist (LAMA)
干预措施: Umeclidinium bromide 62.5mcg (Drug)
Umeclidinium bromide
Experimental
Long-acting muscarinic antagonist (LAMA)
干预措施: Umeclidinium bromide 125mcg (Drug)
结局指标
主要结局
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
时间窗: Baseline and Day 85
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline, and day by treatment interactions.
次要结局
- Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84(Baseline and Day 84)
- Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12(Baseline and Weeks 1- 12)
- Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12(Baseline and Weeks1- 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 WeeksPulmonary Disease, Chronic ObstructiveNCT01772134GlaxoSmithKline617
已完成
2 期
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentPulmonary Disease, Chronic ObstructiveNCT02164539GlaxoSmithKline338
已完成
4 期
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD PatientsPulmonary Disease, Chronic ObstructiveNCT02799784GlaxoSmithKline236
已完成
3 期
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)Chronic Obstructive Pulmonary DiseaseNCT01045161AstraZeneca544
已完成
4 期
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT02153489AstraZeneca30